Triple
T23186576
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | George D. Yancopoulos |
E579607
|
entity |
| Predicate | notableWork |
P4
|
FINISHED |
| Object | Regeneron’s VelociSuite antibody discovery technologies |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Regeneron’s VelociSuite antibody discovery technologies | Statement: [George D. Yancopoulos, notableWork, Regeneron’s VelociSuite antibody discovery technologies]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Regeneron’s VelociSuite antibody discovery technologies Context triple: [George D. Yancopoulos, notableWork, Regeneron’s VelociSuite antibody discovery technologies]
-
A.
VelocImmune technology
chosen
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
Cambridge Antibody Technology
Cambridge Antibody Technology was a pioneering UK biotechnology company best known for developing human monoclonal antibody technologies that led to blockbuster therapeutic drugs.
-
C.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
D.
HyperAcute cellular immunotherapy platform
HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e245ff8000819090d12008805315b7 |
completed | April 17, 2026, 2:38 p.m. |
| NER | Named-entity recognition | batch_69f18fd3aaa08190b9cf7afe4ee5a38d |
completed | April 29, 2026, 4:57 a.m. |
Created at: April 17, 2026, 4:05 p.m.